More Changes at Novartis
.jpg)
Earlier this year, Dan Vasella, the longtime CEO of the Swiss drug maker Novartis, announced that he was resigning his CEO position to assume a full time role as the Chairman of the company’s board of directors. Joe Jimenez, an American, was appointed as the new CEO.
Today, Novartis announced the departure of Ludwig Hanston, the CEO of the US pharma business unit for the past two years. In addition to his departure, four new business units will be formed and 250 employees will lose their jobs effective May 1, 2010.
The four new business units are being formed to more accurately reflect the needs of patient populations. The new business units include 1) Primary Care, 2) Multiple Sclerosis, 3) Psychiatry/Neuroscience and 4) Respiratory/Transplant/Infectious Disease.
For a more detailed explanation of the changes taking place at Novartis please read the post on today’s Pharmalot blog.
Hat tip to Ed.
Until next time…
Good Luck and Good Job Hunting!!!!!
